Triphase Accelerator, together with its majority shareholder FACIT, announced a new strategic collaboration with Celgene for a first-in-class preclinical therapeutic targeting the WDR5 protein for the treatment of blood cancers including leukemia.    Under the terms of the agreement, Celgene has the option to acquire TRPH-395 from Triphase Accelerator. Celgene will pay an upfront of $40M and upon exercise of the option, Celgene will pay up to US$940M in contingent development, regulatory...